The American Heart Association (AHA) and the American College of Cardiology (ACC) have released the first-ever joint clinical guidance for Cardiovascular-Kidney-Metabolic (CKM) syndrome, a framework designed to address the interconnected nature of heart disease, chronic kidney disease, and metabolic disorders. This new construct replaces fragmented treatment approaches with a unified, risk-based classification system aimed at early intervention across the lifespan, according to the official statement published in Circulation.
The 2023 AHA/ACC multisociety guidelines represent a departure from traditional models that often treat obesity, diabetes, and hypertension as isolated conditions. By defining CKM syndrome as a systemic health state, the organizations seek to standardize how clinicians screen for and manage patients who are at risk for progressive organ damage. The guidelines were formally released on November 13, 2023, during the American Heart Association’s Scientific Sessions.
Defining the CKM Syndrome Framework
At the core of the new guidance is a five-stage system—ranging from Stage 0 to Stage 4—that classifies patients based on their metabolic risk factors, kidney function, and documented cardiovascular disease. Stage 0 represents individuals with no identified CKM risk factors, while Stage 4 indicates patients with established cardiovascular disease combined with kidney failure, often requiring dialysis or transplantation, as detailed in the official AHA clinical release.
The shift toward this integrated model addresses the high prevalence of these conditions in the global population. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death globally, and the new guidelines emphasize that metabolic health—specifically obesity and type 2 diabetes—acts as a primary driver for both renal and cardiac decline. By grouping these conditions, the ACC and AHA aim to encourage primary care providers and specialists to collaborate on comprehensive treatment plans that go beyond managing a single biomarker, such as blood pressure or blood sugar alone.
Clinical Management and Risk Stratification
The guidelines introduce specific protocols for risk stratification that prioritize the preservation of kidney and heart function. For patients in the early stages of CKM syndrome, the focus is on weight management, dietary intervention, and physical activity. As patients progress through the stages, the guidance incorporates the use of pharmacotherapies such as SGLT2 inhibitors and GLP-1 receptor agonists, which have demonstrated significant benefits in both cardiovascular and renal outcomes in recent clinical trials.
The American College of Cardiology noted that the staging system is intended to be dynamic. Because CKM syndrome is progressive, patients can move between stages depending on the success of interventions. This fluid approach allows clinicians to adjust intensity levels—shifting from lifestyle counseling to intensive medical therapy—based on the patient’s current stage of systemic health.
Implications for Public Health Policy
Beyond the clinical exam room, the CKM syndrome framework has significant implications for healthcare policy and resource allocation. By identifying patients at earlier stages, health systems can potentially reduce the long-term burden of end-stage renal disease and heart failure, which represent some of the highest costs in modern medicine. The guidelines emphasize the necessity of social determinants of health, such as access to healthy food and safe environments for physical activity, as fundamental components of managing CKM risk.
This holistic approach aligns with current international efforts to address non-communicable diseases. As noted by the World Health Organization, the management of integrated metabolic risks is essential for achieving global targets for reducing premature mortality from cardiovascular disease. The new ACC/AHA framework provides the clinical infrastructure necessary to implement these population-level goals at the individual patient level.
Next Steps for Clinical Implementation
The adoption of the CKM syndrome framework will likely influence future updates to other specialty guidelines, including those for diabetes management and nephrology. The AHA and ACC have stated that this is a living document, and they expect to update the recommendations as new evidence from ongoing clinical trials becomes available. The next major update or review cycle for these guidelines will be announced through the official Circulation journal portal.
As healthcare systems begin to integrate these recommendations, clinicians are encouraged to utilize the new staging tools during routine physical examinations to identify patients who may benefit from early, multidisciplinary care. For readers looking for more information, the full text of the guideline is publicly accessible through the American Heart Association’s professional website.
How do you view the shift toward integrated health models in your own medical practice or patient experience? Please share your thoughts and join the discussion below.